Bulletin
Investor Alert

London Markets Open in:

Market Pulse Archives

Jan. 11, 2021, 7:22 a.m. EST

Lilly's stock jumps 15% after experimental Alzheimer's drug shows it can slow cognitive decline

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Eli Lilly & Co. (LLY)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Eli Lilly & Co. /zigman2/quotes/200106384/composite LLY -0.34% gained 15.4% in premarket trading on Monday after the drugmaker said its experimental Alzheimer's disease drug helped slow the decline of cognition and daily function in patients with early forms of the disease when compared to those taking a placebo. Donanemab, an antibody-based treatment, targets the N3pG beta amyloid; it is currently being tested in a Phase 2 clinical trial, and Lilly said it expects to share full data from the study in the future. There are currently no treatments that slow cognitive decline that have been approved by the Food and Drug Administration. Lilly has studied Alzheimer's treatments for years, but like all pharmaceutical companies, it has struggled to find therapies that work against the disease. A year ago, another Lilly drug, solanezumab, failed a Phase 2/3 trial testing the treatment in people with or at risk for dominantly inherited Alzheimer's disease. Lilly's stock is up 20.6% over the last year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -2.45% has gained 19.7%.

/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 203.82
-0.70 -0.34%
Volume: 2.39M
Feb. 25, 2021 4:04p
P/E Ratio
30.00
Dividend Yield
1.67%
Market Cap
$196.02 billion
Rev. per Employee
$701,137
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,829.34
-96.09 -2.45%
Volume: 2.92B
Feb. 25, 2021 5:19p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.